Fig. 1
14-3-3 \(\upzeta /\updelta\) is upregulated in early disease stages. A 14-3-3 \(\upzeta /\updelta\) CSF levels in CUY, CU, MCI, and AD. Wilcoxon test with FDR-correction for multiple comparisons was used for statistical comparisons. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. B 14-3-3 \(\upzeta /\updelta\) CSF levels in A − T − N −, A + T − N −, A + T + N −, and A + T + N + according to the A/T/N framework using [18F]AZD4694, [18F]MK6240 and hippocampal volume. Wilcoxon test against A − T − N − with FDR-correction for multiple comparisons was conducted. *P < 0.05, **P < 0.01. C Correlation of matrix of depicted synaptic proteins in the CSF of all included participants. Color represents correlation coefficient; all correlations were significant with a P < 0.05. Spearman correlation was used. D–K Spearman correlation analysis of CSF levels of 14-3-3 \(\upzeta /\updelta\) with hippocampal volume (D), cortical [18F]AZD4694 SUVR (E), Braak I [18F]MK6240 SUVR (F), Braak II [18F]MK6240 SUVR (G), Braak III [18F]MK6240 (H), Braak IV [18F]MK6240 SUVR (I), Braak V [18F]MK6240 (J), Braak VI [18F]MK6240 SUVR (K) in cognitively impaired and unimpaired participants. P-values and correlation coefficients are shown in the figure. CUY = cognitively unimpaired young, CU = cognitively unimpaired, MCI = mild cognitive impairment, AD = Alzheimer’s disease, SNAP25 = synaptosomal-associated protein of 25 kDa, NPTX1 = neuronal pentraxin 1, NPTX2 = neuronal pentraxin 2, NPTXR = neuronal pentraxin receptor